Jerry Jones reveals 2010 cancer diagnosis in new documentary
In an episode of "America's Team: The Gamble and His Cowboys," the 10-part documentary series scheduled to premier next Tuesday, Jones mentions that he underwent cancer treatment "about a dozen years ago."
On Wednesday morning, the Dallas Morning News reported that Jones overcame stage 4 melanoma after a decade-long battle beginning with his diagnosis in 2010.
"I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy]," Jones told the Dallas Morning News. "I went into trials for that PD-1 and it has been one of the great medicines.
"I now have no tumors."
REVIEW: 'America's Team' Netflix series a fascinating look at Jerry Jones, Cowboys
According to the American Cancer Society, PD-1 therapy targets the PD-1 protein on immune cells.
PD-1 is a "checkpoint protein" that can prevent immune cells called "T cells" from attacking normal cells. However, some cancer cells have enough of PDL-1, a different protein that bonds with PD-1 and allows it to prevent attacks from the immune system.
The goal of checkpoint protein-related therapy is to block PD-1 from bonding with PDL-1, essentially allowing the body's immune system to attack other cells more freely. The aim is to "help the immune system to better find and attack the cancer cells, wherever they are in the body," but it can lead to some brutal side effects as the immune system might attack other, healthy cells in the body.
Jones' stage 4 cancer diagnosis means that the cancer cells from his melanoma had spread to other parts of his body, which is what led to his four surgeries surgeries on his lungs and lymph nodes.
According to the American Cancer Society, melanoma patients who have had their cancer metastasize to "distant parts of the body, such as the lungs, liver, or skin, or lymph nodes" have a five-year survival rate of 35%. Jones was one of the fortunate survivors of his battle.
This article originally appeared on USA TODAY: Cowboys documentary reveals Jerry Jones' cancer diagnosis in 2010
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Pregnant Woman, 29, Thought She Had Morning Sickness. Then, She Was Diagnosed with a Fast-Growing Cancer
"I went from looking at prams and cots to looking at wigs," the woman told SWNS NEED TO KNOW A pregnant woman who thought she had morning sickness was eventually diagnosed with a fast-growing cancer Sophia Yasin, 29, of Middlesbrough, England, said she was experiencing intense nausea, night sweats and itchiness before her diagnosis She said people around her assured her that her symptoms were 'normal' and would subside with time A pregnant woman thought her extreme nausea was simply morning sickness — until she received a life-altering cancer diagnosis. Sophia Yasin, 29, of Middlesbrough, England, became pregnant in June 2024. The housing support worker and her husband had just purchased a home, and they were looking forward to the future ahead, per SWNS. It was around that time when Sophia began experiencing a host of unpleasant symptoms. "I was [vomiting] all day, every few hours. I was getting night sweats and itchiness through the night. I was very uncomfortable,' she told the outlet. Sophia said people around her told her not to worry, reassuring her that this was all 'normal.' "Everyone told me it was very normal in the first trimester and should ease up,' she recalled, adding, 'I did have some worry, but I thought it was normal for my first pregnancy.' However, her situation took a sudden turn when she collapsed at work at the beginning of her second trimester. "I remember seeing black, and I blacked out,' she told SWNS. Sophia was rushed to the local hospital, where doctors initially suspected she had pneumonia. However, scans and a biopsy revealed that she had a tumor over her heart. She was diagnosed with pre-mediastinal large B-cell non-Hodgkin's lymphoma — a type of cancer that affects the lymphatic system — in September 2024. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "I remember saying, 'What does this mean for the baby?' I remember being numb,' Sophia said. The doctors told Sophia that the tumor over her heart was growing fast, and that she needed to begin chemotherapy immediately if she had any chance of survival. However, treatment could also harm or lead to the death of her unborn child. Sophia and her husband ultimately made the difficult decision to terminate the pregnancy based on the many medical variables at hand. While Sophia was devastated by the loss of her pregnancy, she also acknowledged that it may have saved her life. 'Because I was pregnant, I was prioritized [within the health care system]. In a way, because I was pregnant, they found the cancer in time," she told SWNS. Sophia said she was forced to fight for her next chapter while also grieving the loss of what could have been. "I was grieving a baby but trying to have treatment,' she recalled. She added, 'I lost a lot in a short period of time. I went from looking at prams and cots to looking at wigs. I lost my hair, my baby and my old life." Sophia officially went into remission in January 2025 after six rounds of chemotherapy — but she said she has not forgotten the baby she lost — a daughter whom she and her husband named Kainaat Pearl. She told the outlet that she would like to try for a child again, but that doctors have advised her to wait two years, as there is an increased risk of the cancer returning within that window. Sophia has since established a GoFundMe for a fundraising walk to benefit Lymphoma Action, a U.K. charity dedicated to lymphoma. 'Last summer, my world changed forever,' Sophia wrote on the fundraising page. 'In the midst of what should have been one of the happiest times of my life, I faced the unimaginable: fighting for my life while having to say goodbye to my baby girl, Kainaat Pearl.' 'Every step we take is for Kainaat, for those still fighting and for those we've lost,' she added. The GoFundMe has raised $1,356 toward a goal of $1,490. Read the original article on People
Yahoo
3 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
3 hours ago
- Yahoo
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival
